Company attributes
Other attributes
Instead of growing plants to make cannabinoids, Hyasynth engineer strains of yeast to produce it. After the yeast strains grows, they isolate pure cannabinoids for research, or for products like oils and pills.
Hyasynth is a Licensed Dealer under the Narcotic Control Regulations of Health Canada. Under these regulations, Hyasynth is permitted to produce and distribute cannabinoid products to those that are also legally allowed to possess cannabinoid products.
Their stated goal is to create a new way of producing cannabinoids that doesn't depend on growing plants or doing synthetic chemistry.
There are many cannabinoids, terpenes and combinations of these compounds.
Hyasynth has raised over $1M. The lead investors were Anges Quebec, a local angel network that put in $392,000 from its members and their first round of investors, which include SOSV, Ethan O. Perlstein (CEO of Perlara), and Andrew Hessel from Autodesk.
